THE ROLE OF CLIENT-CENTRED PSYCHOTHERAPY IN THE MANAGEMENT OF PANIC DISORDER

Size: px
Start display at page:

Download "THE ROLE OF CLIENT-CENTRED PSYCHOTHERAPY IN THE MANAGEMENT OF PANIC DISORDER"

Transcription

1 UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE PhD Thesis Abstract THE ROLE OF CLIENT-CENTRED PSYCHOTHERAPY IN THE MANAGEMENT OF PANIC DISORDER PHD COORDINATOR: Prof. Univ. Dr. Tudor UDRIȘTOIU, M.D., PHD PHD POSTGRADUATE: Oana Dana PANAIT, M.D. CRAIOVA, ROMANIA 21

2 I. General part TABLE OF CONTENTS II. Objectives and method of the study III. Results and discussions IV. Conclusions V. References Key words: panic disorder, client centered psychotherapy, treatment management, selective serotonin re-uptake inhibitors, social functioning. I. GENERAL PART Panic disorder has a twelve-month prevalence of 2.7% and a lifetime prevalence of 4.7%, with higher incidence in females (Kessler et al, 2). The essential feature of panic disorder, according to DSM-IV (American Psychiatric Association), is the presence of recurrent, unexpected panic attacks. There is no specification of the precise frequency of panic attacks to fulfil the criteria for panic disorder in DSM-IV. At least one of the attacks has to be followed by one month or more of the following: persistent concern about having another attack, worry about the consequences of having an attack or a significant change in behaviour. There may also be unfocused anxiety present between the attacks. Panic disorder is generally considered to be a chronic condition; although most patients improve, few seem to achieve full remission (Keller et al 1994, Roy-Byrne and Cowley 1994/9, Pollack and Otto 1997). It is estimated that only one third of the patients remain in full remission, the others have a chronic evolution (episodic course or persistent course) (Katschnig et al 199). The course and outcome of panic disorder are influenced by many factors. Women are twice likely to have recurrence of the disease, after remission (Yonkers et al 1998). Panic disorder patients experience severe social and health consequences, which are comparable in severity and sometimes bigger than those seen in depressed patients. Social and marital functions were significantly impaired, and panic disorder was associated with financial dependency. Panic disorder patients subjectively experienced poor physical and emotional health. There was an increased risk of suicide, alcohol and drug abuse, as well as use of psychotropic medication (such as tranquillizers) (Markowitz et al 1989). These patients appear to be more severely impaired than patients with other anxiety disorders. Disability in relation to work is also extensive. Panic disorder patients are more likely to be unemployed or to earn less than normal people who do the same jobs. Therefore, understanding the extent to which panic disorder affects patients lives as a whole is a key issue when it comes to treatment. Several psychopharmacological agents are available for the treatment of panic disorder, among them the selective serotonin reuptake inhibitors (SSRIs) are the first-line drugs. Their efficacy has been proven in many controlled studies, and they are considered to be first-line drugs for this disorder. Psychotherapy has proven to be effective and client centred therapy is one method to be considered. II. OBJECTIVES AND METHOD OF THE STUDY 2.1.Objective The main objective: the comparative evaluation of two groups of patients with panic disorder, along 48 weeks, one of them treated with SSRI and the other one with SSRI and client centred therapy. Secondary objectives: The global evaluation of therapy. The evaluation of the social and professional functioning. 2

3 2.2. Methodological background Prospective study of patients diagnosed with panic disorder, treated only with SSRI (group A) and with SSRI and client centred therapy (group B). The study was 48 weeks long, between February 24-February Inclusion criteria Diagnostic of panic disorder with/without agoraphobia according to DSM-IV Age of 18 at least Able to understand the instructions from the scales and to accept psychotherapy. COVI score at least 9 at screening CGI-S score at least 4 la at screening Exclusion criteria: Without important co-morbidities, or therapeutic-controlled co-morbidities. Without psychiatric co-morbidities. No substances dependency in the last 6 months. 2.. Recorded characteristics Age:2-29 years, 3-39 years and 4-49 years; Residence: rural, urban; Educational background: elementary, college, university. Alcohol consumption: abstinence, occasionally (1-2 times/week), chronic (more than 3 times/week). Years from the beginning of the disorder Scales of evaluation COVI scale Panic and Agoraphobia Scale (PAS). Panic and Agoraphobia Scale-patient questionnaire. Clinical Global Impression Severity Scale. Index of anxiety R-IMA-36. Sheehan Disability Scale (SDS) Study design The subjects were evaluated along seven visits S, S4, S8 within 4 weeks, and S12, S24, S36 and S48 within 12 weeks. Visit S- after signing the inform consent: Inclusion and exclusion criteria Medical history Psychiatric history Previous treatments Demographic data Employment Level of education Residence: rural/urban Clinic general examination COVI PAS PAS-patient questionnaire R-IMA-36 CGI-S SDS 3

4 Visits S4-S48: Maintaining the inform consent COVI PAS PAS-patient questionnaire R-IMA-36 CGI-S SDS Possible adverse events Paroxetine treatment Alprazolam treatment Participation in the therapy sessions for the group B patients. The results were processed separately for each group, related to the recorded characteristics, and comparative, looking for the evolution in time of the scores on all the scales, at each visit 2.8. Study groups Group A: 41 patients: 1 male and 26 de female Age years, with an average mean of 33.+/-7.1 Treatment with paroxetine 2-4 mg/day for 48 weeks Treatment with alprazolam,.2-.mg/day for a short period No psychotherapy. Group B: 3 patients: 9 males and 21 females Age years with an average mean of 33+/- 6,6 Treatment with paroxetine 2-4 mg/day for 36 weeks Treatment with alprazolam,.2-.mg/day for a short period Client centred psychotherapy for 48 weeks. III. RESULTS AND DISCUSSIONS The patients age from both groups is situated between 3-39, namely 3% from group B and 44% from group A. Group A (treated only with SSRI) has a uniform distribution, while 86% from group B patients (treated with SSRI and client centred therapy) are under 39 years of age. The sex distribution was the same in both groups; the share of female is almost double. Regarding the level of instruction, in group A prevail the patients which graduated from highschool, and in the other group the university graduated patients. The majority of both groups (9% from A and 1% from B) have urban residence, the disorder has a history of at least years in both groups. In general, there were no significant differences regarding the demography of both groups Comparative evolution of the groups COVI scale The COVI scores have a descendent trend for both groups, demonstrating the symptoms remission and treatment s efficacy (Fig. nr. 1). The scores were almost equal in the beginning of the study 13.1 for group A and for group B. At a global assessment, group A has a more constant evolution along the 48 study weeks, with a slower rhythm in the first 24 weeks; the B group has a marked improvement of the panic symptoms in the first 24 weeks, the majority of the patients have similar scores as the normal people at week 36. This demonstrates that client centred therapy had an important role in the therapeutic management of panic disorder. 4

5 Media aritmetică ponderată Media aritmetică ponderată ,1 12,829 11,33 1 1,973 9,33 7,267 8,39 4,6 6,22 4,439 3,433 3,1 3,634 S S4 S8 S12 S24 S36 S48 Fig. nr. 1. COVI score evolution in the two groups In a comparative study from 21, Teusch shows that both treatment methods are effective in diminishing both panic and anxiety and avoidance behaviour. The differences between the two groups consisted from the personality scales: the degree of autonomy was bigger in the patients with combined treatment (SSRI and client centred therapy), the patients felt more independent, less stressed, with fewer somatic complaints (Teusch and al. 21). PAS scale The scores on this scale have a more constant evolution for group A; the most important changes for all the patients are in the first 12 weeks of treatment, when the symptoms have a significant improvement (%) and then the rhythm decreases. The symptoms diminishing is bigger between week for group B, the scores average improving by 26.6% (only by 2% for group A), and between week for group A (Fig. nr. 2) ,146 29,133 26, ,733 17,76 19,67 14, 11,8 4,878 6,167,78 1,,3 S S4 S8 S12 S24 S36 S48 Fig. nr. 2. PAS score evolution in the two groups In general, both groups have a clear improvement of panic symptoms along the study; in group A the improvement rhythm is constant and the treatment efficacy is better if the period of administration is at least 12 months (Ballenger, 24). The evolution of group B patients is more rapid, at week 36 they have normal PAS scores; the psychotherapy is helping them to master the anxiety symptoms and the avoidance behaviour.

6 Media aritmetică ponderată Media aritmetică ponderată PAS-patient questionnaire For all the patients the scores on this scale are dropping by % in the first 12 weeks. For the group B patients the improvement of the symptoms is by 3% between weeks 12-24, and for group A is 33%. In the next 12 weeks the difference is the same (% for the group A and 69% for the group B), the role of client centred therapy is shown in the fact that the patients feel more social accepted, more independent in all the activities out their secure environment, with fewer somatic complaints (Mitte, 2). In the last 12 weeks the ratio changes: 7% for group A and 3% for group B (Fig. nr. 3) ,24 27,244 28,933 22,91 23,667 19,267 18,488 14,933 12,341 6,433,366 1,22 1,967,6 S S4 S8 S12 S24 S36 S48 Fig. nr. 3. PAS patient questionnaire score evolution in the two groups R-IMA-36 scale In general, the group A has a more constant evolution along the 48 weeks; for this patients the scores average drops in the first 12 weeks by 3%, while in group B it drops by %. The intensity of panic attacks and of the somatic complaints continues to diminish for these patients by % in the next 12 weeks, but for the group A the decrease is only by 31%. Between week the difference is the same (% for group A and 6% for group B), the therapeutical intervention has an important role in the disappearance of panic attacks and agoraphobia (Mitte, 2). In the last 12 weeks the R-IMA-36 score diminishes by % for both groups (Fig.4) ,22 3,2 27,91 24,4 23,488 19,171 17,833 13,171 13,467 7,6 7,98 3,488 2,967 1,467 S S4 S8 S12 S24 S36 S48 Fig. nr. 4. R-IMA-36 evolution in the two groups 6

7 Media aritmetică ponderată Media aritmetică ponderată CGI-S Panic disorder is a chronic disorder which needs treatment, but, under these conditions, its prognosis is good (Andersch and Hetta, 23). The clinical global assessment shows the symptoms improvement in both groups, with a descendent course for all patients (Fig. nr. ) ,293,1 3,41 3, ,77 2,7 2,98 2,267 1,667 1,488 1,267 1,24 1,24 S S4 S8 S12 S24 S36 S48 Fig. nr.. CGI-S score evolution in the two groups In general, both groups have a similar evolution in the 48 study weeks. For all the patients the scores drop by % in the first 12 weeks, more for the group B, proving that client centred therapy is favourable. In the last 12 weeks group A has a better improvement (33% and group B only 23%). The group B patients have a more rapid course, they report the disappearance of panic attacks and the avoidance behaviour and the somatic complaints (Teusch, 21). SDS The evaluation of the social, professional and familial impact of the disorder on the SDS shows the improvement of these items in both groups (Fig.6) ,97 24,3 21,82 2, 18,82 16,6 16,31 13,8 11,39 8,43 6,41 4,2 4,6 2,9 S S4 S8 S12 S24 S36 S48 Fig. nr. 6. SDS score evolution in the two groups We see that the level of disability decreases, so the social functioning is increasing in both groups the first 12 weeks, by 33% for the A patients and by 4% for the patients benefiting from therapy. The same course is seen in the next 24 weeks; in the last 12 weeks the rhythm is more rapid for group A-37% and only 3% for group B. 7

8 Both groups show an improvement of the social functioning in the 48 study weeks, improvement which is more rapid in group B patients. The rapid recovery is important because the specific panic disorders disabilities are related to the quality of life decreasing (Rubin and al. 2). A cost/efficacy study in two groups of panic disorder patients treated one group with monotherapy (SSRI or psychotherapy) and the other with combined therapy showed that monotherapy is more effective in the acute phase, and the combined treatment in the long-term treatment (McHugh and al. 27). IV. CONCLUSIONS 1. The symptoms improvement (both panic attacks and anxiety) of the group B patients from group B were more rapid. The considerable differences between the two groups, in the group B favour, support the scales conclusions, proving the superiority of the combined therapy in the treatment of panic disorder. 2. Patients treated with SSRI and client centred therapy have a rapid improvement of the social functioning. 3. In the management of panic disorder it has to be considered the association of psychotherapy and pharmacotherapy, because the therapeutic response is quicker and the time of administration of SSRI is shorter. 4. The superiority of combined therapy regarding patients functionality suggests that in the therapeutic management of panic disorder we have to consider beyond the clinical efficacy, the improvement of the social and familial functioning.. Panic disorder responded both to the SSRI treatment and to the combined therapy. 6. Regarding the global social functioning, we see a balance between familial and social dysfunction in both groups, with an important impact on quality of life. 7. Patients functioning is a basic aspect to evaluate, and it is an important marker for adequate therapeutic intervention in panic disorder. V. REFERENCES 1. APA. 2. Diagnostic and statistical manual of mintal disorderrs. 4th ed. Text Revision ( DSM-IV-TR). Washington, DC: American Psychiatric Press. 2. Ballenger JC. 24. Remission rates in patients with anxiety disorder treated with paroxetine. J Clin Psychiatry 6: Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Ruther E. 27a. Meta-analysis of randomized controlled comparaisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry 8: Gendlin ET. Experiential psychotherapy In R. Corsini(Ed.), Current psyvhotherapies Itasca, IL: Peacock.. Greenberg PE, Sisitsky T, Kessler RC, Finkelsteien SN, Berndt ER, Davidson JRT, Ballenger JC, Fyer AJ The economic burden of anxiety disorders in the 199s. J Clin Psychiatry 6: Kasper S, Resinger E. 21. Panic disorder: the place of bezodiazepines and selective serotonin reuptake inhibitors. Eur Neurolpsychopharmacol 11: Lecrubier Y, Judge R Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigation. Acta Psychiatr Scand 9: Lietaer G. Unconditional positive regard: a controversial basic attitude in client-centerd therapy In R. E. Levant and J. M Shilen(Eds), Client-Centered Therapy and the Person-Centered Approach: New Directions in Theory, Research and Practice. New York: Prager. 9. Mitte K. 2. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 88:

9 1. Nutt DJ, Cowen PJ Diazepam alters brain -HT function in man: implications for the acute and chronic effects of benzodiazepines. Psychol Med 17: Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, et al Paroxetine in the treatment of panic disorder. A randomized, Double-blind, placebocontrolled study. Br J Psychiatry 167: Rogers CR. Client-Centered Therapy. Boston: Houghton Mifflin, Rogers CR The necessary and sufficient for therapeutic personality change. Journal of Consulting Psychology 21: Reiman EM, Raichle ME, Robins E et al. 1989b. Neuroanatomical correlates of a lactateinduced anxiety attack. Arch Gen Psychiatry 46: Simon NM, Otto MW, Smits JA, Nicolau DC, Reese HE, Pollack MH. 24. Changes in anxiety sensitivity with pharmacotherapy for panic disorder. J Psychiatr Res 38: Shear MK, Cooper AM, Klerman GL et al A psychodynamic model of panic disorder. Am J Psychiatry 1: Stein MB, Walker JR, Anderson G et al Childhood phisical abuse in patints with anxiety disorders and in a community sample. Am J Psychiatry 13: Teusch L, Bohme H, Finke J. 21. Conflict-centered individual therapy or integration of psychotherapy methods. Process of change in client-centered psychotherapy wit hand without behavioral exposure therapy in agoraphobia with panic disorder. Nervenarzt 72: Wittchen HU. 22. Generalized anxiety disorder: prevalence, burden and cost to society. Depress Anxiety 16: CURRICULUM VITAE PERSONAL INFORMATION Name: Dr. Oana Dana Panait Nationality: Romanian Date of birth: June 19-th, 1968 Marital status: Married Contact: ; oana.panait19@gmail.com Language: Romanian, English, French. EDUCATION: University of Craiova Faculty of Medicine, Romania resident in psychiatry, University Clinic of Psychiatry, Craiova 2-present-psychiatry specialist, University Clinic of Psychiatry, Craiova training in client centred therapy, The Austrian Client-Centred Psychotherapy Association WORKING EXPERIENCE: Emergency Hospital, Craiova 199-present-University Clinic of Psychiatry, Craiova 9

Pharmacological treatment of anxiety disorders where is

Pharmacological treatment of anxiety disorders where is Pharmacological treatment of anxiety disorders where is the room for improvement? David S Baldwin, Professor of Psychiatry BAP Masterclass, 15 th April 2011 dsb1@soton.ac.uk Declaration of interests (last

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008

The legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release

More information

Anxiety Disorders. Fear & Anxiety. Anxiety Disorder? 26/5/2014. J. H. Atkinson, M.D. Fear. Anxiety. An anxiety disorder is present when

Anxiety Disorders. Fear & Anxiety. Anxiety Disorder? 26/5/2014. J. H. Atkinson, M.D. Fear. Anxiety. An anxiety disorder is present when Anxiety s J. H. Atkinson, M.D. HIV Neurobehavioral Research Center University of California, San Diego Department of Psychiatry & Veterans Affairs Healthcare System, San Diego Materials courtesy of Dr.

More information

PHD THESIS STUDY ON THE USE OF THE PHARMACOLOGIC THERAPY WITH BUPROPION ON TOBACCO ABSTINENCE FOR SMOKERS WITH HIGH NICOTINE DEPENDENCE

PHD THESIS STUDY ON THE USE OF THE PHARMACOLOGIC THERAPY WITH BUPROPION ON TOBACCO ABSTINENCE FOR SMOKERS WITH HIGH NICOTINE DEPENDENCE THE UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA PHD THESIS STUDY ON THE USE OF THE PHARMACOLOGIC THERAPY WITH BUPROPION ON TOBACCO ABSTINENCE FOR SMOKERS WITH HIGH NICOTINE DEPENDENCE SCIENTIFIC COORDINATOR:

More information

Clonazepam Augmentation Of Paroxetine In The Treatment Of Panic Disorder: A One Year Naturalistic Follow-Up Study

Clonazepam Augmentation Of Paroxetine In The Treatment Of Panic Disorder: A One Year Naturalistic Follow-Up Study ISPUB.COM The Internet Journal of Mental Health Volume 2 Number 2 Clonazepam Augmentation Of Paroxetine In The Treatment Of Panic Disorder: A One Year Naturalistic P Dannon, I Iancu, K Lowengrub, R Amiaz,

More information

Clomipramine and fluoxetine effects in the treatment of panic disorder

Clomipramine and fluoxetine effects in the treatment of panic disorder Clomipramine and fluoxetine effects in the treatment of panic disorder Semra ^avaljuga 1, Ifeta Li~anin 2, Elvedina Kapi} 3, and Dubravka Potkonjak 3 1. Institute of Epidemiology and Biostatistics, Faculty

More information

Anxiety Disorders: First aid and when to refer on

Anxiety Disorders: First aid and when to refer on Anxiety Disorders: First aid and when to refer on Presenter: Dr Roger Singh, Consultant Psychiatrist, ABT service, Hillingdon Educational resources from NICE, 2011 NICE clinical guideline 113 What is anxiety?

More information

Improving Patient Education and Access to Anxiety Treatment

Improving Patient Education and Access to Anxiety Treatment University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2014 Improving Patient Education and Access to Anxiety Treatment Heather Gardiner University

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium escitalopram, 5mg, 10mg, and 20mg tablets and 10mg/ml oral drops (Cipralex) No. (406/07) Lundbeck Ltd 7 September 2007 The Scottish Medicines Consortium has completed its

More information

Department of Psychiatry & Behavioral Sciences. University of Texas Medical Branch

Department of Psychiatry & Behavioral Sciences. University of Texas Medical Branch Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division

More information

Quality ID #411 (NQF 0711): Depression Remission at Six Months National Quality Strategy Domain: Effective Clinical Care

Quality ID #411 (NQF 0711): Depression Remission at Six Months National Quality Strategy Domain: Effective Clinical Care Quality ID #411 (NQF 0711): Depression Remission at Six Months National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:

More information

PANIC DISORDER is a common

PANIC DISORDER is a common Sertraline in the Treatment of Panic Disorder A Flexible-Dose Multicenter Trial ORIGINAL ARTICLE Mark H. Pollack, MD; Michael W. Otto, PhD; John J. Worthington, MD; Gisele Gus Manfro, MD; Robert Wolkow,

More information

Are Anti depressants Effective in the Treatment of Depressed Patients Who Do Not Seek Psychotherapy?

Are Anti depressants Effective in the Treatment of Depressed Patients Who Do Not Seek Psychotherapy? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Are Anti depressants Effective in the

More information

Studie 083 (950E-CNS )

Studie 083 (950E-CNS ) Studie 083 (950E-CNS-0005-083) Studienberichtssynopse Clinical Study Report 950E-CNS-0005-083 EFFECTS OF THE USE OF REBOXETINE AS A SUBSTITUTE FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTIDEPRESSANTS

More information

Guilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.

Guilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant. 1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number

More information

Defense mechanisms and symptom severity in panic disorder

Defense mechanisms and symptom severity in panic disorder ACTA BIOMED 2010; 81: 30-34 Mattioli 1885 O R I G I N A L A R T I C L E Defense mechanisms and symptom severity in panic disorder Marco Fario, Sonja Aprile, Chiara Cabrino, Carlo Maggini, Carlo Marchesi

More information

Are psychological treatments of panic disorder efficacious?

Are psychological treatments of panic disorder efficacious? Are psychological treatments of panic disorder efficacious? Peter Wilhelm 7.3.2018 PD Dr. Peter Wilhelm, Spring 2018 1 Efficacy of Behavioral Treatment of Panic Disorder First randomised controlled trial

More information

for anxious and avoidant behaviors.

for anxious and avoidant behaviors. Summary of the Literature on the Treatment of Anxiety Disorders in Children and Adolescents Sucheta D. Connolly, M.D.* Non-OCD anxiety disorders in youth are common and disabling, with 12-month prevalence

More information

THERAPEUTIC AND EVOLUTIVE ASPECTS IN SCHIZOPHRENIA

THERAPEUTIC AND EVOLUTIVE ASPECTS IN SCHIZOPHRENIA UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA THERAPEUTIC AND EVOLUTIVE ASPECTS IN SCHIZOPHRENIA ABSTRACT Ph.D. Coordinator Professor Dragoș MARINESCU PhD Student: Mihai MUTICĂ Craiova 2016 TABLE OF CONTENTS

More information

Measurement-based Scales in Major Depressive Disorder:

Measurement-based Scales in Major Depressive Disorder: This program is paid for by Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka Pharmaceutical Development and Commercialization, Inc.

More information

Depression & Anxiety

Depression & Anxiety Depression & Anxiety Depression and Generalized Anxiety Disorder are frequently overlap Mixed anxiety and depression disorder (MAD) has been recognized in ICD-10 as a diagnostic group including those anxious

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Age as factor in selective mutism, 623 as factor in social phobia, 623 Agoraphobia, 593 600 described, 594 596 DSM-V changes related to,

More information

Case #1. Case #1. Case #1. Discussion. DSM IV Overview of PD. Psychopharmacology of Panic Disorder and Generalized Anxiety Disorder 09/03/2012

Case #1. Case #1. Case #1. Discussion. DSM IV Overview of PD. Psychopharmacology of Panic Disorder and Generalized Anxiety Disorder 09/03/2012 Case #1 Psychopharmacology of Panic Disorder and Generalized Anxiety Disorder Smit S. Sinha MD Assistant Professor A 33 year old male engineer presents to an outpatient clinic for consultation for severe

More information

Document Title Pharmacological Management of Generalised Anxiety Disorder

Document Title Pharmacological Management of Generalised Anxiety Disorder Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)

More information

Increasing the Recognition of Generalized Anxiety Disorder in Primary Care

Increasing the Recognition of Generalized Anxiety Disorder in Primary Care University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2015 Increasing the Recognition of Generalized Anxiety Disorder in Primary Care Sarah Rosner

More information

Bipolar Disorder Clinical Practice Guideline Summary for Primary Care

Bipolar Disorder Clinical Practice Guideline Summary for Primary Care Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,

More information

Session 3: Help Me, Doc - I ve Got High Anxiety! Learning Objectives

Session 3: Help Me, Doc - I ve Got High Anxiety! Learning Objectives Session 3: Help Me, Doc - I ve Got High Anxiety! Learning Objectives 1. Recognize the distinguishing features of common anxiety disorders seen in primary care. 2. Use screening measures for diagnosis of

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Lam RW, Levitt AJ, Levitan RD, et al. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized

More information

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

MEDICATION ALGORITHM FOR ANXIETY DISORDERS Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON

More information

Comorbidity of Depression and Other Diseases

Comorbidity of Depression and Other Diseases Comorbidity of Depression and Other Diseases JMAJ 44(5): 225 229, 2001 Masaru MIMURA Associate Professor, Department of Psychiatry, Showa University, School of Medicine Abstract: This paper outlines the

More information

Treating Depression in Disadvantaged Women: What is the evidence?

Treating Depression in Disadvantaged Women: What is the evidence? Treating Depression in Disadvantaged Women: What is the evidence? Megan Dwight Johnson, MD MPH Associate Professor Medical Director, UWMC Inpatient Psychiatry Department of Psychiatry and Behavioral Sciences

More information

Panic disorder is a chronic and recurrent illness associated

Panic disorder is a chronic and recurrent illness associated CLINICAL PRACTICE GUIDELINES Management of Anxiety Disorders. Panic Disorder, With or Without Agoraphobia Epidemiology Panic disorder is a chronic and recurrent illness associated with significant functional

More information

Effectiveness of Cognitive Behaviour Therapy on Patients Suffering From Depression

Effectiveness of Cognitive Behaviour Therapy on Patients Suffering From Depression The International Journal of Indian Psychology ISSN 2348-5396 (e) ISSN: 2349-3429 (p) Volume 3, Issue 4, No. 64, DIP: 18.01.119/20160304 ISBN: 978-1-365-32519-9 http://www.ijip.in July-September, 2016

More information

Comparison of Different Antidepressants and Psychotherapy in the Short-term Treatment of Depression

Comparison of Different Antidepressants and Psychotherapy in the Short-term Treatment of Depression ORIGINAL COMPARISON PAPER OF DIFFERENT ANTIDEPRESSANTS AND PSYCHOTHERAPY IN THE SHORT-TERM TREATMENT OF DEPRESSION Comparison of Different Antidepressants and Psychotherapy in the Short-term Treatment

More information

CONSEQUENCES OF MARIJUANA USE FOR DEPRESSIVE DISORDERS. Master s Thesis. Submitted to: Department of Sociology

CONSEQUENCES OF MARIJUANA USE FOR DEPRESSIVE DISORDERS. Master s Thesis. Submitted to: Department of Sociology CONSEQUENCES OF MARIJUANA USE FOR DEPRESSIVE DISORDERS Master s Thesis Submitted to: Department of Sociology Virginia Polytechnic Institute and State University In partial fulfillment of the requirement

More information

Suitable dose and duration of fluvoxamine administration to treat depression

Suitable dose and duration of fluvoxamine administration to treat depression PCN Psychiatric and Clinical Neurosciences 1323-13162003 Blackwell Science Pty Ltd 572April 2003 1098 Dose and duration of fluvoxamine S. Morishita and S. Arita 10.1046/j.1323-1316.2002.01098.x Original

More information

Proceedings of the International Conference on RISK MANAGEMENT, ASSESSMENT and MITIGATION

Proceedings of the International Conference on RISK MANAGEMENT, ASSESSMENT and MITIGATION COGNITIVE-BEHAVIOURAL THERAPY EFFICACY IN MAJOR DEPRESSION WITH ASSOCIATED AXIS II RISK FACTOR FOR NEGATIVE PROGNOSIS DANIEL VASILE*, OCTAVIAN VASILIU** *UMF Carol Davila Bucharest, ** Universitary Military

More information

TITLE: Buspirone for the Treatment of Anxiety: A Review of Clinical Effectiveness, Safety, and Cost-Effectiveness

TITLE: Buspirone for the Treatment of Anxiety: A Review of Clinical Effectiveness, Safety, and Cost-Effectiveness TITLE: Buspirone for the Treatment of Anxiety: A Review of Clinical Effectiveness, Safety, and Cost-Effectiveness DATE: 03 May 2012 CONTEXT AND POLICY ISSUES Generalized Anxiety Disorder (GAD) is a chronic

More information

CITIES, HEALTH AND WELL-BEING NOVEMBER 2011

CITIES, HEALTH AND WELL-BEING NOVEMBER 2011 CITIES, HEALTH AND WELL-BEING NOVEMBER 2011 Stress and the city PD Dr. Mazda Adli Dept. of Psychiatry and Psychotherapy, CCM Universitätsmedizin Berlin Definition of Stress Stress is an unspecific physical

More information

Routine general practice care for panic disorder within the lifestyle approach to managing panic study

Routine general practice care for panic disorder within the lifestyle approach to managing panic study Routine general practice care for panic disorder within the lifestyle approach to managing panic study Rodney A. Lambert Faculty of Medicine and Health, University of East Anglia, Norwich, UK Abstract

More information

Prevalence of anxiety and depressive symptoms in men with erectile dysfunction

Prevalence of anxiety and depressive symptoms in men with erectile dysfunction Prevalence of anxiety and depressive symptoms in men with erectile dysfunction K Pankhurst, MB ChB G Joubert, BA, MSc P J Pretorius, MB ChB, MMed (Psych) Departments of Psychiatry and Biostatistics, University

More information

Management Science Letters

Management Science Letters Management Science Letters 3 (2013) 1659 1664 Contents lists available at GrowingScience Management Science Letters homepage: www.growingscience.com/msl The effectiveness of worry exposure in treating

More information

Effective Treatment of Depression in Older African Americans: Overcoming Barriers

Effective Treatment of Depression in Older African Americans: Overcoming Barriers Effective Treatment of Depression in Older African Americans: Overcoming Barriers R U T H S H I M, M D, M P H A S S I S T A N T P R O F E S S O R, D E P A R T M E N T O F P S Y C H I A T R Y A N D B E

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update 1 Guideline title Anxiety: management of generalised anxiety disorder in adults in primary, secondary and community care (update)

More information

depression and anxiety in later life clinical challenges and creative research

depression and anxiety in later life clinical challenges and creative research 2 nd Annual MARC Symposium Critical Themes in Ageing Melbourne, 10 th August 2018 depression and anxiety in later life clinical challenges and creative research Nicola T Lautenschlager, MD, FRANZCP Professor

More information

Panic Disorder with or without Agoraphobia

Panic Disorder with or without Agoraphobia Panic Disorder with or without Agoraphobia LPT Gondar Mental Health Group www.le.ac.uk Panic Disorder With and Without Agoraphobia Panic disorder Panic versus anxiety Agoraphobia Agoraphobia without panic

More information

PREVALENCE OF POST TRAUMATIC STRESS DISORDER AMONG BASRAH MEDICAL STUDENTS

PREVALENCE OF POST TRAUMATIC STRESS DISORDER AMONG BASRAH MEDICAL STUDENTS THE MEDICAL JOURNAL OF BASRAH UNIVERSITY PREVALENCE OF POST TRAUMATIC STRESS DISORDER AMONG BASRAH MEDICAL STUDENTS Asaad Q. Al-Yassen, Aqeel Ibrahim Salih ABSTRACT Background Post traumatic stress disorder

More information

Reviews/Evaluations. Guidelines for Cost-Effective Use of Antidepressants. Current Utilization (January 1, 2002 through December 31, 2002)

Reviews/Evaluations. Guidelines for Cost-Effective Use of Antidepressants. Current Utilization (January 1, 2002 through December 31, 2002) Reviews/Evaluations Guidelines for Cost-Effective Use of Antidepressants Current Utilization (January 1, 2002 through December 31, 2002) OHP spent $54 million on antidepressant medications (Class 11) Drug

More information

Managing Anxiety Disorder in Primary Care

Managing Anxiety Disorder in Primary Care Saturday General Session Managing Anxiety Disorder in Primary Care Chris Ticknor, MD Private Practice, Psychiatry Adjunct Professor of Psychiatry UT Health Science Center at San Antonio San Antonio, Texas

More information

Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative

Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Robert I. Simon, M.D.* Suicide risk is increased in patients with Major Depressive Disorder with Melancholic

More information

Developing mental health care in Europe - what can Germany learn from Member States and how can Member States profit from German experience?

Developing mental health care in Europe - what can Germany learn from Member States and how can Member States profit from German experience? Developing mental health care in Europe - what can Germany learn from Member States and how can Member States profit from German experience? Prof. Dr. Rainer Richter De-medicalising primary mental health

More information

June 2015 MRC2.CORP.D.00030

June 2015 MRC2.CORP.D.00030 This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka America Pharmaceutical, Inc. June 2015 MRC2.CORP.D.00030 advice or professional

More information

Pregabalin As A Treatment for Generalized Anxiety Disorder. Ashley Storrs PGY III December 2, 2010

Pregabalin As A Treatment for Generalized Anxiety Disorder. Ashley Storrs PGY III December 2, 2010 Pregabalin As A Treatment for Generalized Anxiety Disorder Ashley Storrs PGY III December 2, 2010 Background Information Approximately 18.1 percent of American adults 18 years or older have an anxiety

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating

More information

Pharmacoeconomic evaluation of venlafaxine compared with citalopram in generalized anxiety disorder

Pharmacoeconomic evaluation of venlafaxine compared with citalopram in generalized anxiety disorder 840 Pharmacoeconomic evaluation of venlafaxine compared with citalopram in generalized anxiety disorder JINGJING ZHANG, HONGBING XU and ZHIQING CHEN Department of Psychological Medicine, Shanghai First

More information

A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression

A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression REVIEW ARTICLE Drug Saf 2011; 34 (9): 709-731 0114-5916/11/0009-0709/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression

More information

THE UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA

THE UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA THE UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA POSTGRADUATE SCHOOL Ph.D. THESIS SUMMARY Supervisor: PROF. UNIV. DR. TUDOR UDRIȘTOIU Ph.D. Student: DR. MOȚĂȚĂIANU (DRAGAN) MARIANA CRAIOVA, 2014 THE UNIVERSITY

More information

Page 1 of 5. Policies Repository. Policy. Policy Description. Policy Guideline Inclusion

Page 1 of 5. Policies Repository. Policy. Policy Description. Policy Guideline Inclusion Page 1 of 5 Policies Repository Policy Title Policy Number Duloxetine (Cymbalta ) FS.CLIN.48 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product line,

More information

Behavior Therapy for Generalized Anxiety Disorder with problematic use of Anxiolytics; Case series

Behavior Therapy for Generalized Anxiety Disorder with problematic use of Anxiolytics; Case series Behavior Therapy for Generalized Anxiety Disorder with problematic use of Anxiolytics; Case series Hiroaki Harai M.D. Address correspondence; Hiroaki Harai MD. Kikuti National Hospital Fukuhara 208 Koushi-Machi

More information

2) Percentage of adult patients (aged 18 years or older) with a diagnosis of major depression or dysthymia and an

2) Percentage of adult patients (aged 18 years or older) with a diagnosis of major depression or dysthymia and an Quality ID #370 (NQF 0710): Depression Remission at Twelve Months National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Prevention, Treatment, and Management of Mental Health

More information

The Economics of Mental Health

The Economics of Mental Health The Economics of Mental Health Garrett Hill Spring 2016 1 Note from the Author Throughout this paper there will be multiple references to common mental illnesses and serious mental illnesses. The author

More information

Outline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions

Outline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions Outline Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly Michael E. Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania and Philadelphia

More information

The Future of CBT in the Age of the DSM-5. Stefan G. Hofmann, Ph.D. Professor of Psychology Boston University

The Future of CBT in the Age of the DSM-5. Stefan G. Hofmann, Ph.D. Professor of Psychology Boston University The Future of CBT in the Age of the DSM-5 Stefan G. Hofmann, Ph.D. Professor of Psychology Boston University 1 Carving Nature at Its Joints Reasons for Classifying Mental Disorders Common language to reliably

More information

foreword general general Six Persimmons 六柿圖 other modalities of treatments by evidence or impression? anxiety disorders drugs benzodiazepines

foreword general general Six Persimmons 六柿圖 other modalities of treatments by evidence or impression? anxiety disorders drugs benzodiazepines Clinical Updates Management of Anxiety Disorders John So - Psychiatrist foreword Six Persimmons 六柿圖 MuqiFachang 牧谿法常 after Zen meditation mindfulness other trends of psychotherapy other modalities of treatments

More information

Developing a new treatment approach to binge eating and weight management. Clinical Psychology Forum, Number 244, April 2013.

Developing a new treatment approach to binge eating and weight management. Clinical Psychology Forum, Number 244, April 2013. Developing a new treatment approach to binge eating and weight management Clinical Psychology Forum, Number 244, April 2013 Dr Marie Prince 1 Contents Service information Binge Eating Disorder Binge Eating

More information

Identifying Adult Mental Disorders with Existing Data Sources

Identifying Adult Mental Disorders with Existing Data Sources Identifying Adult Mental Disorders with Existing Data Sources Mark Olfson, M.D., M.P.H. New York State Psychiatric Institute Columbia University New York, New York Everything that can be counted does not

More information

Multistate Outcome Analysis of Treatment MOAT

Multistate Outcome Analysis of Treatment MOAT Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability

More information

CBT FOR PRIMARY CARE PART 1: BACKGROUND AND THEORY DISCLOSURES

CBT FOR PRIMARY CARE PART 1: BACKGROUND AND THEORY DISCLOSURES CBT FOR PRIMARY CARE PART 1: BACKGROUND AND THEORY Neil Skolnik, M.D. Professor of Family and Community Medicine Temple University School of Medicine Associate Director Family Medicine Residency Program

More information

How to measure mental health in the general population? Reiner Rugulies

How to measure mental health in the general population? Reiner Rugulies How to measure mental health in the general population? Reiner Rugulies National Research Centre for the Working Environment, Denmark Department of Public Health and Department of Psychology, University

More information

Screening for psychiatric morbidity in an accident and emergency department

Screening for psychiatric morbidity in an accident and emergency department Archives of Emergency Medicine, 1990, 7, 155-162 Screening for psychiatric morbidity in an accident and emergency department GARY BELL, NICK HINDLEY, GITENDRA RAJIYAH & RACHEL ROSSER Department of Psychiatry,

More information

The Emperor s New Drugs: Medication and Placebo in the Treatment of Depression

The Emperor s New Drugs: Medication and Placebo in the Treatment of Depression The Emperor s New Drugs: Medication and Placebo in the Treatment of Depression Irving Kirsch, PhD Associate Director, Program in Placebo Studies Harvard Medical School Professor Emeritus of Psychology

More information

An adult version of the Screen for Child Anxiety Related Emotional Disorders (SCARED-A)

An adult version of the Screen for Child Anxiety Related Emotional Disorders (SCARED-A) Netherlands Journal of Psychology / SCARED adult version 81 An adult version of the Screen for Child Anxiety Related Emotional Disorders (SCARED-A) Many questionnaires exist for measuring anxiety; however,

More information

Overview of Generalized Anxiety Disorder: Epidemiology, Presentation, and Course. Risa B. Weisberg, PhD

Overview of Generalized Anxiety Disorder: Epidemiology, Presentation, and Course. Risa B. Weisberg, PhD Risa B. Weisberg Overview of Generalized Anxiety Disorder: Epidemiology, Presentation, and Course Risa B. Weisberg, PhD Generalized anxiety disorder (GAD) was defined relatively recently, and the diagnostic

More information

The Practitioner Scholar: Journal of Counseling and Professional Psychology 1 Volume 5, 2016

The Practitioner Scholar: Journal of Counseling and Professional Psychology 1 Volume 5, 2016 The Practitioner Scholar: Journal of Counseling and Professional Psychology 1 Assessing the Effectiveness of EMDR in the Treatment of Sexual Trauma Shanika Paylor North Carolina Central University and

More information

Diabetes Specific Features. Dealing with Diabetes and Depression. Diabetes Nepal Depression. Overview. Depression. Risk factors for Depression

Diabetes Specific Features. Dealing with Diabetes and Depression. Diabetes Nepal Depression. Overview. Depression. Risk factors for Depression Nepal 13 Dealing with and Overview Prevalence of and Potential Mechanisms Consequences of co-morbidity Clinical Implications Richard IG Holt Professor in and Endocrinology Nepal, Kathmandu 16 February

More information

Epidemiology and Economic Impact of Anxiety Disorders

Epidemiology and Economic Impact of Anxiety Disorders CNS NEWS NOVEMBER 2006 31 Recognition and Treatment of Anxiety Disorders In the Primary Care Setting JOINT SPONSORSHIP STATEMENT Jointly presented by The Johns Hopkins University School of Medicine and

More information

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care CLINICAL ASSESSMENT AND DIAGNOSIS (ADULTS) Obsessive-Compulsive Disorder (OCD) is categorized by recurrent obsessions,

More information

Robert Heinssen, PhD, ABPP North Carolina Practice Improvement Collaborative North Carolina State University, Raleigh NC November 7, 2014

Robert Heinssen, PhD, ABPP North Carolina Practice Improvement Collaborative North Carolina State University, Raleigh NC November 7, 2014 Robert Heinssen, PhD, ABPP North Carolina Practice Improvement Collaborative North Carolina State University, Raleigh NC November 7, 2014 Disclosures I have no personal financial relationships with commercial

More information

Guideline for the Diagnosis and Management of Generalized Anxiety Disorder for Primary Care Physicians

Guideline for the Diagnosis and Management of Generalized Anxiety Disorder for Primary Care Physicians MAGELLAN BEHAVIORAL HEALTH/ BLUE CROSS BLUE SHIELD OF NORTH CAROLINA Guideline for the Diagnosis and Management of Generalized Anxiety Disorder for Primary Care Physicians This guideline includes recommendations

More information

Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant

Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island

More information

Post-traumatic stress disorder A brief overview

Post-traumatic stress disorder A brief overview THEME: Trauma and loss Post-traumatic stress disorder A brief overview Simon Howard, Malcolm Hopwood BACKGROUND Post-traumatic stress disorder (PTSD) is an anxiety disorder which occurs following exposure

More information

Are psychological treatments of panic disorder efficacious?

Are psychological treatments of panic disorder efficacious? Are psychological treatments of panic disorder efficacious? Peter Wilhelm 7.3 and 14.3.2018 PD Dr. Peter Wilhelm, Spring 2018 1 Efficacy of Behavioral Treatment of Panic Disorder First randomised controlled

More information

Assessment in Integrated Care. J. Patrick Mooney, Ph.D.

Assessment in Integrated Care. J. Patrick Mooney, Ph.D. Assessment in Integrated Care J. Patrick Mooney, Ph.D. Purpose of assessment in integrated care: Assessment provides feedback to promote individual and group learning and change. Physicians Mental health

More information

Jonathan Haverkampf OCD OCD. Dr Jonathan Haverkampf, M.D.

Jonathan Haverkampf OCD OCD. Dr Jonathan Haverkampf, M.D. Dr, M.D. Obsessive-Compulsive Disorders () can interfere significantly with a patient s life but has a reputation of being more difficult to treat. However, with a combination of psychotherapy and medication

More information

Anxiety Disorders.

Anxiety Disorders. Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner

More information

Undertreatment of Panic Disorder in Primary Care: Role of Patient and Physician Characteristics

Undertreatment of Panic Disorder in Primary Care: Role of Patient and Physician Characteristics Undertreatment of Panic Disorder in Primary Care: Role of Patient and Physician Characteristics Peter Roy-Byrne, MD, Joan Russo, PhD, David C. Dugdale, MD, Daniel Lessler, MD, Deborah Cowley, MD, and Wayne

More information

DESCRIPTION OF FOLLOW-UP SAMPLE AT INTAKE SECTION TWO

DESCRIPTION OF FOLLOW-UP SAMPLE AT INTAKE SECTION TWO SECTION TWO DESCRIPTION OF FOLLOW-UP SAMPLE AT INTAKE 7 2.1 DEMOGRAPHIC CHARACTERISTICS Table 2.1 presents demographic descriptive data at intake for those who were included in the follow-up study. Data

More information

Anxiety disorders in mothers and their children: prospective longitudinal community study

Anxiety disorders in mothers and their children: prospective longitudinal community study Anxiety disorders in mothers and their children: prospective longitudinal community study Andrea Schreier, Hans-Ulrich Wittchen, Michael Höfler and Roselind Lieb Summary The relationship between DSM IV

More information

1 1 Evidence-based pharmacotherapy of major depressive disorder. Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A.

1 1 Evidence-based pharmacotherapy of major depressive disorder. Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A. 1 1 Evidence-based pharmacotherapy of major depressive disorder Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A. Nierenberg Massachusetts General Hospital and Harvard University, Boston,

More information

FAMILY AND ADOLESCENT MENTAL HEALTH: THE PEDIATRICIAN S ROLE

FAMILY AND ADOLESCENT MENTAL HEALTH: THE PEDIATRICIAN S ROLE FAMILY AND ADOLESCENT MENTAL HEALTH: THE PEDIATRICIAN S ROLE Mark Cavitt, M.D. Medical Director, Pediatric Psychiatry All Children s Hospital/Johns Hopkins Medicine OBJECTIVES Review the prevalence of

More information

Illuminating the Black Box: Antidepressants, Youth and Suicide

Illuminating the Black Box: Antidepressants, Youth and Suicide Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, M.D. Executive Director, MGH Psychiatry Academy Director, Postgraduate Medical Education Director, Child and Adolescent Psychiatry

More information

INSTRUCTION MANUAL Instructions for Patient Health Questionnaire (PHQ) and GAD-7 Measures

INSTRUCTION MANUAL Instructions for Patient Health Questionnaire (PHQ) and GAD-7 Measures PHQ and GAD-7 Instructions P. 1/9 INSTRUCTION MANUAL Instructions for Patient Health Questionnaire (PHQ) and GAD-7 Measures TOPIC PAGES Background 1 Coding and Scoring 2, 4, 5 Versions 3 Use as Severity

More information

Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?

Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Prof. Dr. Christoph Hiemke Psychiatrische Klinik und Poliklinik Universität Mainz Psychopharmacotherapy Psychiatric Patient

More information

New Developments in the Treatment of Social Anxiety Disorder. History of SAD Diagnosis DSM-5 SAD. SAD Subtypes

New Developments in the Treatment of Social Anxiety Disorder. History of SAD Diagnosis DSM-5 SAD. SAD Subtypes Clinical Importance of Social Anxiety Disorder (aka Social Phobia) New Developments in the Treatment of Social Anxiety Disorder Franklin Schneier, MD Co-Director, Anxiety Disorders Clinic New York State

More information

Generalized Anxiety Disorder. By, Jennifer Corr

Generalized Anxiety Disorder. By, Jennifer Corr Generalized Anxiety Disorder By, Jennifer Corr What is it? Generalized Anxiety Disorder (GAD) is a disorder where a person can experience constant and chronic worry about everyday life. People often shift

More information

Medication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford

Medication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant

More information

GOALS FOR THE PSCYHIATRY CLERKSHIP

GOALS FOR THE PSCYHIATRY CLERKSHIP GOALS FOR THE PSCYHIATRY CLERKSHIP GOALS - The aim of the core psychiatry clerkship is to expose students to patients with mental illness and to prepare them to provide psychiatric care at a basic level.

More information

PTSD: Treatment Opportunities

PTSD: Treatment Opportunities PTSD: Treatment Opportunities Professor Malcolm Hopwood Department of Psychiatry University of Melbourne Professorial Psychiatry Unit, Albert Road Clinic DSM 5: PTSD CRITERION A exposure to: actual or

More information

Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder

Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder updated 2012 Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder Q10: Are antidepressants (Tricyclic antidepressants

More information

SCREENING FOR ANXIETY IN BC: IS THE EPDS ENOUGH?

SCREENING FOR ANXIETY IN BC: IS THE EPDS ENOUGH? SCREENING FOR ANXIETY IN BC: IS THE EPDS ENOUGH? NICHOLE FAIRBROTHER, PH.D. R.PSYCH. ASSISTANT PROFESSOR UBC DEPARTMENT OF PSYCHIATRY ISLAND MEDICAL PROGRAM TEAM & FUNDING TEAM FUNDING Nichole Fairbrother

More information